Resveratrol modulates the malignant properties of cutaneous melanoma through changes in the activation and attenuation of the antiapoptotic protooncogenic protein Akt/PKB

Melanoma Research

Volumn 21, Issue 3, 2011, Pages 180-187

  Bhattacharya, Saswati ^a,b   Darjatmoko, Soesiawati R ^a,b   Polans, Arthur S ^a,b  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Akt protein kinase B; cutaneous melanoma; resveratrol

Indexed keywords

GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; PROTEIN KINASE B; RESVERATROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER MODEL; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME INACTIVATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN VARIANT; REAL TIME POLYMERASE CHAIN REACTION; TUMOR VOLUME; WESTERN BLOTTING; WOUND HEALING;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; ENZYME ACTIVATION; FEMALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SKIN NEOPLASMS; STILBENES;

EID: 79955627038     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3283456dfc     Document Type: Article

References (30)

1. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010; 116:544-573.
2. Strouse JJ, Fears TR, Tucker MA, Wayne AS. Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database. J Clin Oncol 2005; 23:4735-4741. (Pubitemid 46224077)
3. Guillett SE. Disorders of the Skin. In: Neal LJ, Guillett SE, editors. Care of the adult with a chronic illness or disability: a team approach. St. Louis, MO: Elsevier Mosby; 2004. pp. 63-106.
4. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5:493-506. (Pubitemid 44136961)
5. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 2004; 24:2783-2840. (Pubitemid 39409568)
6. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275:218-220. (Pubitemid 127696281)
7. Tucker MA, Halpern A, Holly EA, Hartge P, Elder DE, Sagebiel RW, et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 1997; 277:1439-1444. (Pubitemid 27208885)
8. Govindarajan B, Sligh JE, Vincent BJ, Li M, Canter JA, Nickoloff BJ, et al. Overexpression of akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest 2007; 117:719-729. (Pubitemid 46348530)
9. Dhawan P, Singh AB, Ellis DL, Richmond A. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res 2002; 62:7335-7342. (Pubitemid 36025257)
10. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64:327-336. (Pubitemid 121001258)
11. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410:50-56. (Pubitemid 32225831)
12. Fidler IJ. Selection of successive tumour lines for metastasis. Nat New Biol 1973; 242:148-149.
13. Poste G, Fidler IJ. The pathogenesis of cancer metastasis. Nature 1980; 283:139-146. (Pubitemid 10171124)
14. Nakamura K, Yoshikawa N, Yamaguchi Y, Kagota S, Shinozuka K, Kunitomo M. Characterization of mouse melanoma cell lines by their mortal malignancy using an experimental metastatic model. Life Sci 2002; 70:791-798. (Pubitemid 34075567)
15. Van Ginkel PR, Darjatmoko SR, Sareen D, Subramanian L, Bhattacharya S, Lindstrom MJ, et al. Resveratrol inhibits uveal melanoma tumor growth via early mitochondrial dysfunction. Invest Ophthalmol Vis Sci 2008; 49:1299-1306.
16. Anderson KE, Coadwell J, Stephens LR, Hawkins PT. Translocation of PDK-1 to the plasma membrane is important in allowing PDK-1 to activate protein kinase B. Curr Biol 1998; 8:684-691. (Pubitemid 28286275)
17. Subramanyam M, Takahashi N, Hasegawa Y, Mohri T, Okada Y. Inhibition of protein kinase Akt1 by apoptosis signal-regulating kinase-1 (ASK1) is involved in apoptotic inhibition of regulatory volume increase. J Biol Chem 2010; 285:6109-6117.
18. Ruoslahti E. Fibronectin in cell adhesion and invasion. Cancer Metastasis Rev 1984; 3:43-51.
19. Bellacosa A, De Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995; 64:280-285.
20. Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, et al. AKT1/ PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 2001; 159:431-437. (Pubitemid 32751073)
21. Meier F, Busch S, Lasithiotakis K, Kulms D, Garbe C, Maczey E, et al. Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br J Dermatol 2007; 156:1204-1213. (Pubitemid 47029801)
22. Liao Y, Hung MC. Physiological regulation of akt activity and stability. Am J Transl Res 2010; 2:19-42.
23. Medina EA, Afsari RR, Ravid T, Castillo SS, Erickson KL, Goldkorn T. Tumor necrosis factor-(alpha) decreases akt protein levels in 3T3-L1 adipocytes via the caspase-dependent ubiquitination of akt. Endocrinology 2005; 146:2726-2735. (Pubitemid 40695576)
24. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene 2005; 24:7443-7454. (Pubitemid 41637984)
25. Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, van Roy F, Lee-Kwon W, et al. The protein kinase akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res 2003; 63:2172-2178. (Pubitemid 36538623)
26. Garlich JR, De P, Dey N, Su JD, Peng X, Miller A, et al. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res 2008; 68: 206-215. (Pubitemid 351380122)
27. Sareen D, Van Ginkel PR, Takach JC, Mohiuddin A, Darjatmoko SR, Albert DM, et al. Mitochondria as the primary target of resveratrol-induced apoptosis in human retinoblastoma cells. Invest Ophthalmol Vis Sci 2006; 47:3708-3716. (Pubitemid 46049513)
28. Busquets S, Ametller E, Fuster G, Olivan M, Raab V, Argiles JM, et al. Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer Lett 2007; 245:144-148. (Pubitemid 44959346)
29. Kimura Y, Okuda H. Resveratrol isolated from polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in lewis lung carcinoma-bearing mice. J Nutr 2001; 131:1844-1849. (Pubitemid 32520456)
30. Subramanian L, Youssef S, Bhattacharya S, Kenealey J, Polans AS, van Ginkel PR. Resveratrol: challenges in translation to the clinic-A critical discussion. Clin Cancer Res 2010; 16:5942-5948.